Dr. Konopleva is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
- Texas Tech University Health Sciences Center at LubbockResidency, Internal Medicine, 2005 - 2008
- St Petersburg Medical State AcademyClass of 1990
Certifications & Licensure
- FL State Medical License 2021 - Present
- NY State Medical License 2022 - 2026
- TX State Medical License 2009 - 2024
- OK State Medical License 2020 - 2021
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2009
Clinical Trials
- RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia Start of enrollment: 2009 Nov 01
- Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias Start of enrollment: 2010 Jun 01
- AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2010 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 287 citationsEffective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitorMatthew R. Janes, Jose J. Limon, Lomon So, Jing Chen, Raymond J Lim
Nature Medicine. 2010-02-01 - 96 citationsHuman extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironmentYe Chen, Rodrigo Jacamo, Yue Xi Shi, Rui Yu Wang, Venkata Lokesh Battula
Blood. 2012-05-24 - 220 citationsReciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance.Rodrigo Jacamo, Ye Chen, Zhiqiang Wang, Wencai Ma, Min Zhang
Blood. 2014-04-24
Journal Articles
- CD123 Expression Patterns and Selective Targeting with a CD123-Specific Antibody-Drug Conjugate (IMGN632) in Acute Lymphoblastic LeukemiaL Jeffrey Medeiros, Hagop M Kantarjian, Jeffrey L Jorgensen, Marina Konopleva, Elias J Jabbour, Joseph D Khoury, Sa A Wang, Sergej N Konoplev, Haematologica
- Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid LeukemiaBrian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood
- Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular SubtypesKoichi Takahashi, Marina Konopleva, Steven Kornblau, Hagop Kantarjian, Nitin Jain, Elias Jabbour, Courtney D DiNardo, Michael Andreeff, Nature
- Join now to see all
Abstracts/Posters
- Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid LeukemiaMarina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 StudyMarina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Metabolism and Hematologic Malignancies60th American Society of Hematology Annual Meeting - 12/2/2018
- Single-Cell Atlas of Driver Mutations in Acute Myeloid Leukemia (AML)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Authored Content
- A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (Pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)October 2017
- MCL-1 up-Regulation Through MAPK Activation Confers Acquired Resistance to BCL-2 Inhibitor ABT-199 in Pre-Clinical AML ModelsOctober 2017
- Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid MalignanciesOctober 2017
- The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017
- Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 Days (SGI5), 10 Days (SGI10), 5 Days + Idarubicin (SGI5 + Ida), and 5 Days + Cladribine (SGI5 + Clad), in Previously Untreated Patients ≥ 70 Years with Acute Myeloid Leukemia (AML)–a Bayesian DesignOctober 2017
- Targeting the Mitochondria Metabolism of T-ALL with Novel Mitochondrial Complex I Inhibitor IACS-010759October 2017
- Join now to see all
Press Mentions
- Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 8th, 2023
- New Leukemia-Killing Compounds DiscoveredJuly 27th, 2022
- Rice University, UT-MD Anderson Cancer Center Researchers Discover New Leukemia-Killing CompoundsJuly 1st, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: